EVFM Evofem Biosciences Inc.

3.6
0  0%
Previous Close 3.6
Open 3.52
Price To Book -9.23
Market Cap 93122093
Shares 25,867,248
Volume 3,011
Short Ratio
Av. Daily Volume 144,839

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 4Q 2019.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
Phase 3 data released December 17, 2018. Primary endpoint met. NDA to be refiled 2Q 2019.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
  2. Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target
  3. Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
  4. Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT
  5. The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
  6. Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
  7. Evofem Shares Up as Birth Control Gel Succeeds in Phase III
  8. Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals
  9. 4 Stocks Providing Investor Opportunity Right Now
  10. Evofem's hormone-free birth control gel meets main goal in key study
  11. Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
  12. Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018
  13. Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
  14. Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  15. Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled
  16. Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018
  17. Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
  18. Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candidate Amphora®
  19. New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
  20. Evofem Biosciences to Present at Upcoming Investor Conferences